Загрузка страницы

CytoDyn sees impressive results with Leronlimab on very ill COVID-19 patients

CytoDyn (OTCQB: CYDY) CEO Dr Nader Pourhassan and IncellDX CEO Dr Bruce Patterson joined Steve Darling from Proactive Vancouver with news that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic biomarkers.

Both Dr Patterson and DR Pourhassen tell Proactive about the study and the next major steps they are planning on taking.

Видео CytoDyn sees impressive results with Leronlimab on very ill COVID-19 patients канала Proactive
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
2 апреля 2020 г. 22:29:20
00:08:18
Яндекс.Метрика